Our Seed probiotics review comes down to this: DS-01 Daily Synbiotic is one of the few probiotics tested as a finished product. In a six-week trial of 350 adults with everyday bloating, it beat placebo on bloating, gas and regularity[1]. All three DS-01 trials were funded by Seed, and none tested people with diagnosed digestive disease.
At $49.99 a month, about $1.67 a day, it is a reasonable option for an otherwise healthy adult whose main complaint is bloating[2]. It is not a proven treatment for IBS, skin or heart conditions, even though its strains are grouped under those headings.
Below: what is in the capsule, what each trial found, what the 24 strains have and have not been tested for, side effects, and who should skip it.
How we reviewed this
We read Seed's product page and its strain reference library in October 2026 for the label, directions and price[2][3]. We read the three published DS-01 trials in full text, the lab study of its capsule, and the published trials on the named strains it contains. We then checked them against the American College of Gastroenterology guideline, a 2023 meta-analysis of 82 probiotic trials in IBS and the NIH fact sheet on probiotics[4][5][6].
We did not test DS-01 hands-on, we did not receive free product, and this page carries no affiliate links.
What is in Seed DS-01?
DS-01 is a two-capsule daily dose: 24 bacterial strains totaling 53.6 billion AFU inside an inner capsule, and 400 mg of Indian pomegranate extract in the outer capsule[3]. Seed groups the strains into four blends and lists a weight and count for each blend, not for each strain[2].
| Blend (Seed's name) | Amount per 2 capsules | Strains | Examples |
|---|---|---|---|
| Digestive Health | 224 mg, 38.7 billion AFU | 16 | Bifidobacterium longum SD-BB536-JP, Lacticaseibacillus rhamnosus SD-GG-BE, Bifidobacterium infantis SD-M63-JP |
| Dermatological Health | 36 mg, 3.34 billion AFU | 4 | Ligilactobacillus salivarius SD-LS1-IT, B. lactis SD-CECT8145-SP |
| Cardiovascular Health | 13 mg, 4.21 billion AFU | 2 | Lactiplantibacillus plantarum SD-LPLDL-UK, B. lactis SD-MB2409-IT |
| Micronutrient Synthesis | 36 mg, 7.32 billion AFU | 2 | B. lactis SD-BA5-IT, Limosilactobacillus reuteri SD-LRE2-IT |
| Prebiotic (outer capsule) | 400 mg | none | Indian pomegranate extract, over 40% polyphenols |
Seed's reference page also shows an older label image with slightly different blend totals, so check the label on the jar you receive[3]. The product page lists the formula as tested for gluten, dairy, nuts, soy, shellfish, sesame, glyphosate and heavy metals, and as compliant with California's Proposition 65[2].
Why "AFU" instead of CFU?
AFU (active fluorescent units) counts cells by flow cytometry, a stain-based method. CFU (colony forming units) counts only cells that grow into colonies on a plate. Plate counts miss cells that are alive but cannot be cultured, while flow cytometry can measure viability through membrane integrity[7].
That makes AFU and CFU numbers hard to compare directly. A higher count is not automatically better: the NIH notes that products with more CFU are not necessarily more effective[6]. Our CFU guide explains how to read probiotic counts.
What makes it a "synbiotic"?
An international expert panel defines a synbiotic as live microorganisms plus a substrate selectively used by host microbes that together confer a health benefit[8].
In DS-01, the substrate is a polyphenol extract rather than a fiber such as inulin. Gut bacteria turn pomegranate polyphenols into urolithins, which is why Seed's trials measured urolithin A[9]. For the general distinction, see our prebiotics vs. probiotics guide.
What do Seed's own clinical trials show?
Three randomized, placebo-controlled trials have tested the complete DS-01 formula. Only one measured symptoms in a large group; the other two were small studies of microbiome and blood markers[1][9][10].
| Trial | Who | Length | Main results | Limits |
|---|---|---|---|---|
| Bloating trial (2026) | 350 adults with self-reported bloating for 3+ months | 6 weeks | Less bloating and gas, less abdominal discomfort, better regularity than placebo | Only 219 evaluable at week 6; self-reported |
| Healthy adults (2025) | 32 healthy adults, 27 analyzed | 91 days | More Bifidobacterium and Lactobacillus diversity; urolithin A up 49-fold | Small; marker outcomes |
| After antibiotics (2026) | 32 healthy adults, 21 analyzed | 91 days | Faster recovery of diversity and butyrate; better gut barrier test | Small; 11 dropouts |
The bloating trial
This is the trial behind Seed's claim that DS-01 relieves bloating, gas and irregularity. At week 6, scores on a validated bloating and gas scale were lower with DS-01 than placebo (median 16 vs. 21), and 72.3% vs. 55.9% said they never or rarely felt bloated[1].
Abdominal discomfort also improved (median 8 vs. 10), and 49.5% vs. 34.2% reported better regularity[1]. There were no serious adverse events, and side effect rates did not differ between groups[1].
Note the large placebo response: bloating scores improved 42.5% from baseline on placebo, against 54.3% on DS-01[1]. Participants did not have a diagnosed digestive disorder, and people taking many common medications were excluded, so the results may not apply to you if you have IBS or take regular medication[1]. See our guide to probiotics for bloating for other strains tested for this symptom.
The microbiome and antibiotic trials
In 32 healthy adults, DS-01 raised the diversity of Bifidobacterium and Lactobacillus species at every time point. Urolithin A production rose 49-fold by day 91, and all DS-01 participants were producing urolithin A by then, compared with 44.4% on placebo[9]. Fecal butyrate rose in people who started with low levels. The lower C-reactive protein reported in the title was an association with strain abundance within the DS-01 group, not a difference from placebo[9].
In the antibiotic trial, everyone took ciprofloxacin and metronidazole for 7 days alongside DS-01 or placebo. The DS-01 group recovered Bifidobacterium and Lactobacillus diversity faster, with 119% more fecal butyrate and a gut permeability test about 50% better than placebo at days 7 and 91[10]. The authors acknowledge that the sample was small with high attrition, and the trial did not report diarrhea as an outcome[10]. Our article on whether antibiotics cause diarrhea covers the strains with clinical evidence for that problem.
Who funded the trials?
Seed funded all three trials, and Seed employees and shareholders are among the authors[1][9][10]. In the bloating trial, an independent research company ran the study and the sponsor had no role in operations[1]. Industry funding does not make a result wrong, but independent replication has not yet been published.
What have the 24 strains been tested for?
Most of DS-01's strains have not been tested individually in published human trials that we could find. A handful carry designations that match well-studied strains. We could not independently confirm that each Seed-coded strain is identical to the strain in the trial, and every trial below used a different product, dose and population.
| Strain in DS-01 | Studied as | Who was studied | What was found |
|---|---|---|---|
| B. longum SD-BB536-JP | BB536 alone | 80 older adults with chronic constipation, 4 weeks | Primary endpoint not met (p=0.074); stool frequency improved |
| B. breve SD-BR3-IT + L. plantarum SD-LP1-IT | BR03 + LP01 | 300 adults with hard stools, 30 days | More weekly bowel movements, easier passage |
| B. infantis SD-M63-JP | M-63 in a 3-strain mix | 48 children with IBS | Abdominal pain resolved more often than placebo |
| L. rhamnosus SD-GG-BE | LGG | 12 trials, 1,499 people on antibiotics | Less antibiotic-associated diarrhea; significant in children only |
| L. salivarius SD-LS1-IT | LS01 | 38 adults with atopic dermatitis, 16 weeks | Improved eczema severity scores |
| Three dermatological strains (CECT 8145, 7347, 9104) | Same 3-strain mix | 50 children with moderate atopic dermatitis | Eczema scores fell 83% vs. 24% on placebo |
| B. lactis SD-CECT8145-SP | CECT 8145 alone | 135 adults with abdominal obesity | Modest BMI and waist changes, mainly in women |
| B. lactis SD-MB2409-IT | MB 2409 in a 3-strain mix | 38 children with high cholesterol | Total cholesterol 3.4% lower |
Digestive strains
The Bifidobacterium longum strain has the most direct link to regularity. In older adults with chronic constipation, BB536 did not improve the overall constipation score significantly, but stool frequency did improve versus placebo[11].
A pairing of Bifidobacterium breve BR03 with Lactobacillus plantarum LP01 increased weekly bowel movements and eased hard stools in 300 adults[12]. Read more on the B. longum and L. plantarum pages, and in our guide to constipation.
Bifidobacterium infantis M-63, combined with two other bifidobacteria, resolved abdominal pain more often than placebo in children with IBS and improved quality of life in 48% vs. 17%[13]. Lactobacillus rhamnosus GG cut antibiotic-associated diarrhea from 22.4% to 12.3% across 12 trials, though the effect in adults was not statistically significant[14].
Skin strains
The skin claims rest on trials in people with diagnosed eczema, not healthy skin. Lactobacillus salivarius LS01 improved eczema severity and quality of life in 38 adults over 16 weeks[15].
A capsule combining the three CECT strains that DS-01 also contains reduced eczema scores by 19.2 points more than placebo in 50 children and cut topical steroid use[16]. The strains' owner funded that trial. See our page on eczema for the wider evidence.
Heart and weight strains
The cardiovascular evidence is thin. B. lactis MB 2409, in a three-strain mix with two strains not in DS-01, lowered total cholesterol by 3.4% in 38 children with dyslipidemia[17]. We found no published human trial for the L. plantarum LPLDL strain.
CECT 8145 alone, at 10 billion CFU a day, produced modest changes in body measures in adults with abdominal obesity, mainly in women[18]. None of this shows that DS-01 lowers cholesterol or weight; if you have high cholesterol, keep following the treatment your clinician recommends.
Is Seed a high-quality probiotic?
On the measures you can check, yes. The label names every strain to the strain level, which the NIH says matters because probiotic effects are strain-specific[6]. The full formula has been tested in randomized trials, which most probiotics have not. Seed also lists allergen, contaminant and heavy-metal testing on its product page[2].
Like every supplement, DS-01 is not FDA-approved: the FDA has no authority to approve dietary supplements before they are sold, and the company is responsible for backing its claims[19].
The capsule design, meant to shield bacteria from stomach acid, has lab support but not human proof. In a lab model of the stomach and small intestine, the capsule released only a small fraction of cells in the stomach compartment, and live counts after the small intestine matched the capsule's starting count[20]. Seed funded that study and its employees were authors[20].
Two gaps remain. The label does not give the amount of each strain, and the testing laboratory is not named on the pages we read. An ISAPP expert panel recommends independent third-party verification of probiotic quality, especially for products used by patients[21].
What are the downsides of Seed probiotics?
The main downsides are cost, a two-capsule dose, an evidence base limited to healthy adults, and a possible adjustment period.
- Evidence scope: the only symptom trial was in otherwise healthy adults with bloating; none were in diagnosed IBS, SIBO or other conditions[1].
- Guideline position: the American College of Gastroenterology suggests against probiotics for overall IBS symptoms[4].
- Unknown per-strain doses: you cannot compare DS-01's dose of any one strain with the dose used in that strain's trial[2].
What are the side effects of Seed probiotics?
Seed warns that some people get temporary gastrointestinal discomfort, abdominal tightness, mild nausea or changes in stool, which it says should settle within the first few weeks[3]. In the 350-person trial, side effect rates did not differ from placebo[1].
If discomfort lasts, Seed suggests taking the capsules with food or splitting them between morning and evening[3]. If symptoms are severe or do not settle, stop and talk to a clinician.
How much does Seed cost monthly?
Seed lists DS-01 at $49.99 for a 30-day supply of 60 capsules, delivered monthly, which works out to about $1.67 a day[2]. The page also offers 3-month and 6-month deliveries[2]. Prices were as listed in October 2026.
How do you take DS-01?
Seed's dosage directions are to take 1 capsule a day for the first three days, then 2 capsules at once daily from day four. Ideally, take both on an empty stomach or at least 10 minutes before a meal[3]. No refrigeration is needed; keep the capsules in the refillable glass jar or travel vial Seed supplies[3][2].
In the trials, the benefits were measured after 6 weeks for symptoms and up to 91 days for microbiome changes, so judge it over weeks, not days[1][9]. Our guide on when to take probiotics covers timing in more detail.
Who should consider Seed, and who should skip it?
DS-01 fits best for an otherwise healthy adult with recurring bloating or irregularity who is willing to pay for a product with a direct trial. That matches the population in its largest study[1].
Talk to a clinician first, or skip it, if you:
- are severely ill, hospitalized or immunocompromised: rare bloodstream infections linked to probiotics have mostly occurred in these groups[6];
- are pregnant, planning a pregnancy or nursing, which Seed itself flags[3];
- take prescription medication or have a medical condition, as Seed also advises[3];
- have diagnosed IBS, where the evidence for probiotics is low to very low certainty[5].
Never stop or change a prescribed medicine to make room for a probiotic.
How does Seed compare with Ritual and other options?
Seed bets on many strains plus a finished-product trial; the alternatives below bet on one or a few strains with longer individual records. Ritual's page lists 11 billion CFU in one capsule a day, against Seed's 53.6 billion AFU in two, and the two counts use different methods[22][2][7].
- For antibiotic-associated diarrhea, single-strain LGG has more trials; see our Culturelle review.
- For IBS-type pain and bloating, see our Align review of B. longum 35624.
- For another multi-strain synbiotic, see our Bioma review.
Which probiotics do doctors recommend?
Gastroenterology guidelines recommend strains for specific uses rather than brands for general health. The American College of Gastroenterology, for example, suggests against probiotics for overall IBS symptoms[4]. The NIH notes that recommendations need to be strain-specific[6]. For a strain-by-strain ranking across goals, see our guide to the best probiotics.
This article is for general educational purposes and is not medical advice. Product details come from the manufacturer's pages as retrieved in October 2026 and may change. Talk to a qualified healthcare professional before starting a probiotic, particularly if you are pregnant, immunocompromised, taking prescription medication, or managing a diagnosed condition.
Frequently Asked Questions
Is Seed probiotic FDA approved?
No, and no dietary supplement is. Under US law the FDA does not have the authority to approve dietary supplements before they are sold. The company is responsible for safety and for having evidence that its claims are truthful. Seed's own trials were published in peer-reviewed journals, but publication is not an FDA review.
Which probiotic is better, Culturelle or Seed?
They answer different questions. Culturelle is built on one strain, Lactobacillus rhamnosus GG, with a long trial record for antibiotic-associated diarrhea, strongest in children. Seed DS-01 combines 24 strains with a pomegranate extract and has one large trial in adults with everyday bloating. If your goal is antibiotic-associated diarrhea, the LGG evidence is deeper; for bloating in otherwise healthy adults, DS-01 has the more direct trial. Our Culturelle review covers LGG in detail.
Who are the three people who should not take probiotics?
There is no official list of three, but sources single out people who are severely ill or hospitalized and people with weakened immune systems, because rare bloodstream infections linked to probiotics have mostly occurred in them. Seed adds a third group for DS-01: anyone pregnant, planning a pregnancy or nursing should check with a doctor first. People taking prescription medication should also ask before starting.
Does Seed probiotic help with weight loss?
No DS-01 trial we found measured weight loss. One of its 24 strains, Bifidobacterium lactis CECT 8145, was tested alone in 135 adults with abdominal obesity, with modest changes in body mass index and waist measures that were seen mainly in women. That trial used a far higher dose of that single strain than is likely in a 24-strain blend, so it does not show that DS-01 causes weight loss.
Is Seed probiotic good for IBS?
There is no published DS-01 trial in people diagnosed with IBS. The large bloating trial enrolled adults without a diagnosed digestive disorder. Separately, the American College of Gastroenterology suggests against probiotics for overall IBS symptoms, because the evidence is weak and inconsistent. If you have IBS, discuss any probiotic with your clinician, and stop if symptoms worsen.
Is Seed probiotic safe during pregnancy?
Seed advises anyone who is pregnant, planning a pregnancy or nursing to talk to their doctor before taking DS-01. Its large bloating trial excluded pregnant and breastfeeding people, so there is no DS-01 data for pregnancy. Ask your obstetric clinician before starting it.
Is there a downside to taking probiotics?
For most healthy adults the main downsides are cost and temporary gas or bloating. In a meta-analysis of 55 IBS trials with more than 7,000 patients, adverse events were not more common with probiotics than placebo. The real risks sit with specific groups: rare bloodstream infections have been reported, mostly in people who were severely ill or immunocompromised.
What is the number one rated probiotic on the market?
There is no single number one probiotic, and no brand is the most trusted for everything, because effects are specific to the strain and the condition. A better test than a rating is whether the label names each strain and whether that exact product or strain was tested for your goal. Our ranking of probiotic strains by clinical evidence compares the main options.
References
- Allegretti JR, Kassam Z, Kelly CR, et al.. A Randomized, Placebo-Controlled Trial Evaluating Multi-Species Synbiotic Supplementation for Bloating, Gas, and Abdominal Discomfort. Nutrients. 2026;18(2):255. doi:10.3390/nu18020255 ↩
- Seed Health. DS-01 Daily Synbiotic. Seed Health (manufacturer website), retrieved October 2026. 2026. Available at: https://seed.com/daily-synbiotic ↩
- Seed Health. Reference Library: DS-01 Daily Synbiotic. Seed Health (manufacturer website), retrieved October 2026. 2026. Available at: https://seed.com/reference/syn-wk ↩
- Lacy BE, Pimentel M, Brenner DM, et al.. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. American Journal of Gastroenterology. 2020;116(1):17-44. doi:10.14309/ajg.0000000000001036 ↩
- Goodoory VC, Khasawneh M, Black CJ, Quigley EM, Moayyedi P, Ford AC. Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis. Gastroenterology. 2023;165(5):1206-1218. doi:10.1053/j.gastro.2023.07.018 ↩
- NIH Office of Dietary Supplements. Probiotics: Fact Sheet for Health Professionals. National Institutes of Health. 2026. Available at: https://ods.od.nih.gov/factsheets/Probiotics-HealthProfessional/ ↩
- Boyte ME, Benkowski A, Pane M, Shehata HR. Probiotic and postbiotic analytical methods: a perspective of available enumeration techniques. Frontiers in Microbiology. 2023;14:1304621. doi:10.3389/fmicb.2023.1304621 ↩
- Swanson KS, Gibson GR, Hutkins R, et al.. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nature Reviews Gastroenterology & Hepatology. 2020;17(11):687-701. doi:10.1038/s41575-020-0344-2 ↩
- Napier BA, Allegretti JR, Feuerstadt P, et al.. Multi-Species Synbiotic Supplementation Enhances Gut Microbial Diversity, Increases Urolithin A and Butyrate Production, and Reduces Inflammation in Healthy Adults: A Randomized, Placebo-Controlled Trial. Nutrients. 2025;17(17):2734. doi:10.3390/nu17172734 ↩
- Napier BA, Allegretti JR, Feuerstadt P, et al.. Multi-Species Synbiotic Supplementation After Antibiotics Promotes Recovery of Microbial Diversity and Function, and Increases Gut Barrier Integrity: A Randomized, Placebo-Controlled Trial. Antibiotics. 2026;15(2):138. doi:10.3390/antibiotics15020138 ↩
- Takeda T, Asaoka D, Nojiri S, et al.. Usefulness of Bifidobacterium longum BB536 in Elderly Individuals With Chronic Constipation: A Randomized Controlled Trial. American Journal of Gastroenterology. 2022;118(3):561-568. doi:10.14309/ajg.0000000000002028 ↩
- Del Piano M, Carmagnola S, Anderloni A, et al.. The Use of Probiotics in Healthy Volunteers With Evacuation Disorders and Hard Stools: A Double-Blind, Randomized, Placebo-Controlled Study. Journal of Clinical Gastroenterology. 2010;44(Suppl 1):S30-S34. doi:10.1097/MCG.0b013e3181ee31c3 ↩
- Giannetti E, Maglione M, Alessandrella A, et al.. A Mixture of 3 Bifidobacteria Decreases Abdominal Pain and Improves the Quality of Life in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. Journal of Clinical Gastroenterology. 2017;51(1):e5-e10. doi:10.1097/MCG.0000000000000528 ↩
- Szajewska H, Kołodziej M. Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Alimentary Pharmacology & Therapeutics. 2015;42(10):1149-1157. doi:10.1111/apt.13404 ↩
- Drago L, Iemoli E, Rodighiero V, Nicola L, De Vecchi E, Piconi S. Effects of Lactobacillus Salivarius LS01 (DSM 22775) Treatment on Adult Atopic Dermatitis: A Randomized Placebo-Controlled Study. International Journal of Immunopathology and Pharmacology. 2011;24(4):1037-1048. doi:10.1177/039463201102400421 ↩
- Navarro-López V, Ramírez-Boscá A, Ramón-Vidal D, et al.. Effect of Oral Administration of a Mixture of Probiotic Strains on SCORAD Index and Use of Topical Steroids in Young Patients With Moderate Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatology. 2018;154(1):37-43. doi:10.1001/jamadermatol.2017.3647 ↩
- Guardamagna O, Amaretti A, Puddu PE, et al.. Bifidobacteria supplementation: Effects on plasma lipid profiles in dyslipidemic children. Nutrition. 2014;30(7-8):831-836. doi:10.1016/j.nut.2014.01.014 ↩
- Pedret A, Valls RM, Calderón-Pérez L, et al.. Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial. International Journal of Obesity. 2018;43(9):1863-1868. doi:10.1038/s41366-018-0220-0 ↩
- US Food and Drug Administration. Questions and Answers on Dietary Supplements. US Food and Drug Administration. 2026. Available at: https://www.fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements ↩
- Bron PA, Catalayud M, Marzorati M, et al.. Delivery of Metabolically Neuroactive Probiotics to the Human Gut. International Journal of Molecular Sciences. 2021;22(17):9122. doi:10.3390/ijms22179122 ↩
- Merenstein D, Pot B, Leyer G, et al.. Emerging issues in probiotic safety: 2023 perspectives. Gut Microbes. 2023;15(1):2185034. doi:10.1080/19490976.2023.2185034 ↩
- Ritual. Synbiotic+. Ritual (manufacturer website), retrieved October 2026. 2026. Available at: https://ritual.com/products/synbiotic-plus-for-gut-health ↩